secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuraxis, INC (NRXS)
CIK:        0001933567
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001493152-24-030873
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeurAxis Q2 revenue down 5.3% to $611.5K; net loss widens to $2.9M; insurance coverage expands to 22.5M lives
--------------------------------------------------------------------------------

- Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.
- Net loss $2.9M, up 30.5% YoY; operating loss $2.2M, up 97.5%.
- Covered lives grew to 22.5M from 4.5M a year ago; commitment from payer with 12M lives starting Oct 1.
- Submitted RED device to FDA for clearance expected Q4 2024; submitted label expansion to ages 8-21.
- Secured additional $3.0M funding in May; total committed financing $9.1M; cash $1.8M, short-term debt $4.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933567/000149315224030873/0001493152-24-030873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933567/000149315224030873/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer